Trial Profile
A study evaluating potential relationships between neutrophil to lymphocyte ratio and progression free survival and overall survival in patients with metastatic non-small cell lung cancer treated with second-line nivolumab or pembrolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology